CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance (in shares) at Sep. 30, 2020		12,404,000
Beginning Balance at Sep. 30, 2020	$ 53,437	$ 12	$ 85,868	$ (32,443)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock unit (in shares)		78,000
Expense related to director restricted stock units	232		232
Expense related to employee stock-based compensation	612		612
Exercise of stock options (in shares)		63,000
Exercise of stock options	231	$ 1	230
Net income	4,381			4,381
Ending Balance (in shares) at Mar. 31, 2021		12,545,000
Ending Balance at Mar. 31, 2021	58,893	$ 13	86,942	(28,062)
Beginning Balance (in shares) at Dec. 31, 2020		12,544,000
Beginning Balance at Dec. 31, 2020	55,935	$ 13	86,551	(30,629)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	116		116
Expense related to employee stock-based compensation	270		270
Exercise of stock options (in shares)		1,000
Exercise of stock options	5		5
Net income	2,567			2,567
Ending Balance (in shares) at Mar. 31, 2021		12,545,000
Ending Balance at Mar. 31, 2021	$ 58,893	$ 13	86,942	(28,062)
Beginning Balance (in shares) at Sep. 30, 2021	12,714,000	12,714,000
Beginning Balance at Sep. 30, 2021	$ 65,608	$ 13	87,893	(22,298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	324		324
Expense related to employee stock-based compensation	$ 985		985
Exercise of stock options (in shares)	26,000	26,000
Exercise of stock options	$ 262		262
Exercise of stock warrants (in shares)		54,000
Exercise of stock warrants	200		200
Net income	$ 14,982			14,982
Ending Balance (in shares) at Mar. 31, 2022	12,794,000	12,794,000
Ending Balance at Mar. 31, 2022	$ 82,361	$ 13	89,664	(7,316)
Beginning Balance (in shares) at Dec. 31, 2021		12,768,000
Beginning Balance at Dec. 31, 2021	74,112	$ 13	88,593	(14,494)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	162		162
Expense related to employee stock-based compensation	647		647
Exercise of stock options (in shares)		26,000
Exercise of stock options	262		262
Net income	$ 7,178			7,178
Ending Balance (in shares) at Mar. 31, 2022	12,794,000	12,794,000
Ending Balance at Mar. 31, 2022	$ 82,361	$ 13	$ 89,664	$ (7,316)